Vanguard Group Inc. raised its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 28.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 847,212 shares of the company's stock after buying an additional 189,227 shares during the quarter. Vanguard Group Inc. owned about 1.53% of Pulse Biosciences worth $7,379,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Griffin Asset Management Inc. boosted its stake in Pulse Biosciences by 15.7% during the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company's stock worth $2,616,000 after acquiring an additional 40,700 shares in the last quarter. Inspire Investing LLC boosted its position in shares of Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after buying an additional 10,039 shares during the last quarter. PNC Financial Services Group Inc. bought a new stake in Pulse Biosciences in the 4th quarter worth about $242,000. Finally, BNP Paribas Financial Markets raised its position in Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock worth $66,000 after buying an additional 2,952 shares during the last quarter. Institutional investors own 76.95% of the company's stock.
Insiders Place Their Bets
In other Pulse Biosciences news, CEO Burke Thomas Barrett purchased 10,000 shares of Pulse Biosciences stock in a transaction dated Monday, May 20th. The stock was purchased at an average price of $8.56 per share, with a total value of $85,600.00. Following the transaction, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $85,600. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 71.50% of the company's stock.
Pulse Biosciences Trading Down 0.4 %
NASDAQ:PLSE traded down $0.08 during trading hours on Friday, reaching $19.01. The company had a trading volume of 157,976 shares, compared to its average volume of 217,529. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -23.47 and a beta of 1.75. The firm's 50 day moving average price is $14.39 and its 200-day moving average price is $10.92. Pulse Biosciences, Inc. has a 52 week low of $3.78 and a 52 week high of $20.44.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Tuesday, August 6th.
View Our Latest Analysis on Pulse Biosciences
Pulse Biosciences Profile
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
